30 million, around 10 000⋯ and 18 ⋯ Figuring out the optimal treatment for musculoskeletal conditions in the National Health Service

Rheumatology

Volumn 46, Issue 8, 2007, Pages 1219-1220

  Isenberg, D A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSENTEEISM; AUTOIMMUNE DISEASE; BACKACHE; COST CONTROL; DRUG COST; EDITORIAL; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH ECONOMICS; HOSPITAL SERVICE; HUMAN; JOINT PROSTHESIS; MUSCULOSKELETAL DISEASE; NATIONAL HEALTH SERVICE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SYNOVECTOMY; TENDON TRANSPLANTATION; TREATMENT PLANNING; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; WORK DISABILITY;

COST OF ILLNESS; GREAT BRITAIN; HUMANS; MUSCULOSKELETAL DISEASES; RHEUMATOLOGY; STATE MEDICINE; WAITING LISTS;

EID: 34547852181     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem083     Document Type: Editorial

References (4)

1. The Musculoskeletal Services Framework. Department of Health Publications; 270211 London 2006.
2. Maini RN, Feldmann M. The immunopathogenesis of rheumatoid arthritis. In: Isenberg DA, Maddison PJ, Woo P, Glass D, Breedveld FC, eds. The Oxford Textbook of Rheumatology, 3rd edn. Oxford: Oxford University Press, 2004;677-96.
3. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B cells. Rheumatology 2001;40:205-11.
4. Walsh D, Kelly C, Bosworth A, Price C, Burbage G. Provisional guidelines for applying the United Kingdom Department of Health 18 week patient pathway to specialist rheumatology care. Rheumatology 2007;46:1200-06.